⚠ COVID-19 INFORMATION: Resources, Vaccine Information

Phase 2 Study of Omalizumab in Oral Peanut Desensitization (PRROTECT)

Official Title: Phase 2 Study of Omalizumab in Oral Peanut Desensitization (PRROTECT)

The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization

ClinicalTrials.gov ID: NCT01781637

Principal Investigator: Pongracic, Jacqueline A., MD

Study Type: Interventional

Currently Recruiting Patients: No

Contact Information:

Jacqueline Pongracic, MD

Principal Investigator

888-573-1833